Fosun Pharma: Controlled subsidiary receives EU approval for additional drug indications

```htmlGolden Ten Data, May 10 — On May 10, Fosun Pharma announced that its controlling subsidiary Shanghai Henlius Biotech, as well as its own controlled subsidiaries, have received approval from the European Commission for two newly added indications for Slulilumab injection (EU trade name: Hetronifly®): 1. Combined with fluorouracil and platinum-based chemotherapy, it is approved as a first-line treatment for adult patients with PD-L1 combined positive score (CPS) ≥5, unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC); 2. Combined with carboplatin and pemetrexed, it is approved as a first-line treatment for adult patients with EGFR gene mutation-negative, ALK or ROS1-negative unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (nsNSCLC). Accordingly, these newly added indications have been approved in all EU member states, as well as Iceland, Liechtenstein, and Norway (all members of the European Economic Area).```